Overview
- The multisite, peer‑reviewed paper published this week in JAMA Network Open tracked 346 adults who completed a single supervised psilocybin session at 24 licensed Oregon service centers and reported symptoms at baseline, one week, one month and three months.
- At one month 91.5% of participants said they benefited and 64.9% ranked the session among their top 10 most meaningful life experiences; by three months the cohort reported large drops in moderate‑to‑severe depression, anxiety and PTSD symptoms and higher life satisfaction.
- Serious physical harms were not reported, but four first‑time users (about 1.2% of the cohort) had adverse behavioral reactions that required medical attention and seven people described the experience as harmful at three months.
- The study is observational with no control group and enrolled about 5% of Oregon’s clients during the study period; participants were self‑selected, demographically skewed, and doses varied (2–50 mg, mean ≈31.9 mg), which limits causal claims and generalizability.
- Researchers have federal funding to continue follow‑up and expand outcomes research, OPEN has begun collecting comparable data in Colorado, and policymakers and counties weighing regulated access face tradeoffs of potential benefit, cost barriers, and uneven local availability.